{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=5", "query": { "intervention": "Placebo film", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 309, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T12:29:07.099Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00134563", "title": "Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for teriflunomide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1088, "start_date": "2004-09", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134563" }, { "nct_id": "NCT01235962", "title": "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Cancer" ], "interventions": [ { "name": "pazopanib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1538, "start_date": "2010-11-30", "completion_date": "2019-04-15", "has_results": true, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 69, "location_summary": "Jonesboro, Arkansas • Antioch, California • Beverly Hills, California + 53 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01235962" }, { "nct_id": "NCT05672576", "title": "A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Cenerimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Viatris Innovation GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 451, "start_date": "2023-06-26", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 17, "location_summary": "Tucson, Arizona • La Jolla, California • Northridge, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672576" }, { "nct_id": "NCT02145468", "title": "A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Losmapimod 7.5 mg twice daily", "type": "DRUG" }, { "name": "Placebo twice daily", "type": "DRUG" }, { "name": "Standard therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 3503, "start_date": "2014-06-03", "completion_date": "2015-12-14", "has_results": true, "last_update_posted_date": "2017-06-02", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 91, "location_summary": "Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Cottonwood", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02145468" }, { "nct_id": "NCT00202696", "title": "Nalmefene Smoking Cessation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "nalmefene", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Somaxon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "25 Years to 65 Years" }, "enrollment_count": 76, "start_date": "2005-09", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2008-05-19", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00202696" }, { "nct_id": "NCT06195072", "title": "Platform Clinical Study for Conquering Scleroderma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Interstitial Lung Disease Due to Systemic Disease", "Scleroderma" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "BI 1015550 (Nerandomilast)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scleroderma Research Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2024-04-15", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06195072" }, { "nct_id": "NCT02169583", "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Respiratory Tract" ], "interventions": [ { "name": "GSK1325756 Solution", "type": "DRUG" }, { "name": "GSK1325756 Solution Matching Placebo", "type": "DRUG" }, { "name": "GSK1325756 Tablet", "type": "DRUG" }, { "name": "GSK1325756 Tablet Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2014-06-12", "completion_date": "2014-08-28", "has_results": false, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169583" }, { "nct_id": "NCT01931839", "title": "A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation" ], "interventions": [ { "name": "Lumacaftor Plus Ivacaftor Combination", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1164, "start_date": "2013-10", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-05-12", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931839" }, { "nct_id": "NCT02616601", "title": "Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "Generic Fluorouracil Cream", "type": "DRUG" }, { "name": "Carac® (Fluorouracil) Cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 422, "start_date": "2015-02-27", "completion_date": "2015-09-17", "has_results": true, "last_update_posted_date": "2019-07-17", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 17, "location_summary": "Fremont, California • Los Angeles, California • San Diego, California + 14 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616601" }, { "nct_id": "NCT02516202", "title": "The Vaginal Health Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrophy of Vagina", "Menopause", "Dyspareunia (Female)" ], "interventions": [ { "name": "Vagifem", "type": "DRUG" }, { "name": "Replens", "type": "DEVICE" }, { "name": "Placebo tablet", "type": "OTHER" }, { "name": "Placebo gel", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "45 Years to 70 Years · Female only" }, "enrollment_count": 302, "start_date": "2016-04", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-10-11T12:29:07.099Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Seattle, Washington", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02516202" } ] }